bendamustine
Bendamustine is a drug used to treat Chronic Lymphocytic Leukemia, Lymphoma, Mantle Cell Lymphoma, and other conditions. Bendamustine is being actively studied in 62 studies and prior, has been studied in 80.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
Hoffmann-La Roche | Samsung Medical Center | Jonathon Cohen |
M.D. Anderson Cancer Center | Centre Henri Becquerel | Adam Olszewski |
German CLL Study Group | Columbia University Medical Center | Antonio Pinto |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
W
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +6 more
- Saint Louis, MissouriWashington University School of Medicine
2021-05-21
May 21, 2021U
Completed
- Multiple Myeloma
- Melphalan
- Bendamustine
- Berne, SwitzerlandDepartment for Medical Oncology University Hospital/Inselspital
2021-07-29
Jul 29, 2021N
Recruiting
- Hairy Cell Leukemia
- Pentostatin
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022U
Recruiting
- Mantle Cell Lymphoma
- +2 more
- Bendamustine
- Obinutuzumab
- Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
2022-03-07
Mar 7, 2022Y
W
Recruiting
- Relapsed T-Cell Lymphoma
- +2 more
- CPI 613
- Bendamustine
- Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
2021-08-27
Aug 27, 2021M
Recruiting
- Lymphoma
- rituximab
- +3 more
- New York, New YorkMemorial Sloan Kettering Cancer Center
2022-03-07
Mar 7, 2022I
Not yet recruiting
- Mantle Cell Lymphoma
- parsaclisib
- +3 more
- (no location specified)
2022-02-14
Feb 14, 2022W
Active, not recruiting
- Mantle Cell Lymphoma
- Bendamustine
- +7 more
- Saint Louis, MissouriWashington University School of Medicine
2022-02-02
Feb 2, 2022S
Not yet recruiting
- Relapsed, Refractory, Multiple Myeloma
- Pomalidomide
- +2 more
- Guangzhou, Please Select, ChinaSun Yat-sen University Cancer Center
2021-02-17
Feb 17, 2021S
Withdrawn
- Indolent Non-Hodgkin's Lymphoma
- +3 more
- Duvelisib
- +3 more
- Plainville, Connecticut
- +6 more
2021-03-15
Mar 15, 2021P
Active, not recruiting
- Indolent Non-hodgkin Lymphoma
- Obinutuzumab
- Bendamustine
- München, Bavaria, GermanyKlinikum der Universität München
2021-07-23
Jul 23, 2021U
Active, not recruiting
- Lymphoid Leukemia
- +2 more
- Bendamustine
- +2 more
- Madison, WisconsinUniversity of Wisconsin
2021-10-07
Oct 7, 2021H
Completed
- Diffuse, Large B-Cell, Lymphoma
- Polatuzumab Vedotin
- +3 more
- Beijing, China
- +9 more
2022-02-09
Feb 9, 2022A
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- Bendamustine
- Alemtuzumab
- Innsbruck, Tirol, Austria
- +6 more
2022-02-15
Feb 15, 2022U
Terminated
- Lymphoid Leukemia
- +3 more
- Copanlisib
- +2 more
- Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
2021-07-20
Jul 20, 2021U
Completed
- Lymphoma, Non-Hodgkin
- Lymphoma
- Carfilzomib
- +2 more
- Davis, California
- +2 more
2021-04-21
Apr 21, 2021D
Completed
- Lymphoma, Follicular
- Bendamustine
- +2 more
- Scarborough, Maine
- +3 more
2021-04-27
Apr 27, 2021P
F
Terminated
- Lymphatic Diseases
- Brentuximab Vedotin
- Bendamustine
- Bologna, BO, Italy
- +4 more
2021-05-26
May 26, 2021A
Active, not recruiting
- Lymphoma, Non-Hodgkin
- +5 more
- Rituximab
- +2 more
- Providence, Rhode IslandRhode Island Hospital and The Miriam Hospital
2021-07-19
Jul 19, 2021G
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
- Cologne, GermanyGerman CLL Study Group
2021-12-13
Dec 13, 2021S
Active, not recruiting
- Non-Hodgkin's Lymphoma
- Bendamustine
- +6 more
- Philadelphia, PennsylvaniaSidney Kimmel Cancer Center at Thomas Jefferson University
2021-06-03
Jun 3, 2021G
Active, not recruiting
- Chronic Lymphocytic Leucemia
- Bendamustine
- +2 more
- Cologne, GermanyGerman CLL Study Group
2021-08-23
Aug 23, 2021U
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
- Bendamustine
- Cyclophosphamide
- Tucson, ArizonaThe University of Arizona Cancer Center
2021-05-10
May 10, 2021